UK markets close in 1 hour 55 minutes

Centessa Pharmaceuticals plc (CNTA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
4.0200-0.0400 (-0.99%)
As of 09:31AM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 379.24M
Enterprise value -37.52M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)0.91
Enterprise value/revenue N/A
Enterprise value/EBITDA 3.65

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-74.48%
S&P500 52-week change 3-15.36%
52-week high 317.7300
52-week low 32.8850
50-day moving average 34.3842
200-day moving average 36.9422

Share statistics

Avg vol (3-month) 3169.94k
Avg vol (10-day) 3181.73k
Shares outstanding 594.34M
Implied shares outstanding 6N/A
Float 840.17M
% held by insiders 13.31%
% held by institutions 176.46%
Shares short (14 Sept 2022) 42.66M
Short ratio (14 Sept 2022) 411.5
Short % of float (14 Sept 2022) 4N/A
Short % of shares outstanding (14 Sept 2022) 42.82%
Shares short (prior month 14 Aug 2022) 42.71M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Jun 2022


Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-22.48%
Return on equity (ttm)-43.77%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -209.4M
Net income avi to common (ttm)-220.09M
Diluted EPS (ttm)-2.2950
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)484.16M
Total cash per share (mrq)5.13
Total debt (mrq)67.4M
Total debt/equity (mrq)16.05
Current ratio (mrq)15.48
Book value per share (mrq)4.46

Cash flow statement

Operating cash flow (ttm)-199.49M
Levered free cash flow (ttm)-110.88M